Coccidiosis vaccines
AssigneeNational Research Development Corporation
InventorMartin W. Shirley
Life of this patent
Estimating the term…
Abstract
Attenuated E. necatrix suitable for use in the production of a live vaccine is produced by passaging pathogenic E. necatrix in embryonated eggs for a sufficient number of passages i.e. from about 20 up to about 50 or more egg passages. The live egg-attenuated E. necatrix of the invention may be formulated in vaccines, e.g. feed or drinking water vaccines, for prevention and control of coccidiosis in poultry, usually with other strains of Eimeria (i.e. E. acervulina, E. brunetti, E. maxima, E. mivali, E. praecose and E. tenella) as live pathogenic strains thereof or preferably attenuated non-pathogenic lines thereof. In a preferred embodiment the egg-attenuated E. necatrix of the invention is formulated in a vaccine comprising attenuated, precocious E. acervulina.
Claims12
A process for the production of an attenuated strain of E. necatrix, which comprises:
- passaging a pathogenic E. necatrix in embryonated eggs for from about 20 to about 60 passages.
A vaccine for the prevention and control of coccidiosis in poultry, which comprises:
- a live attenuated strain of E. necatrix produced by passaging a pathogenic E. necatrix strain in embryonated eggs for from about 20 to about 60 passages.
Dependencies are inferred from the claim text.